tildrakizumab (Ilumetri)

following a full submission:

tildrakizumab (Ilumetri®) is accepted for restricted use within NHSScotland.

Indication under review: The treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy.

SMC restriction: for use in patients who have failed to respond to conventional systemic therapies (including ciclosporin, methotrexate and phototherapy), are intolerant to, or have a contraindication to these treatments.

Tildrakizumab was superior to placebo in improving the signs and symptoms of psoriasis in adults with moderate to severe plaque psoriasis, who were candidates for systemic therapy.

This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of tildrakizumab. This advice is contingent upon the continuing availability of the PAS in NHSScotland or a list price that is equivalent or lower.